PRA HEALTH SCIENCES INC PRAH
December 12, 2019 - 3:09pm EST by
kerrcap
2019 2020
Price: 102.05 EPS 5.10 5.80
Shares Out. (in M): 66 P/E 20.4 17.9
Market Cap (in $M): 6,684 P/FCF 20 18
Net Debt (in $M): 1,200 EBIT 490 540
TEV ($): 7,900 TEV/EBIT 16 14.6

Sign up for free guest access to view investment idea with a 45 days delay.

Description

 

Risks

Biopharma R&D spending slows
Industry M&A
Exposure to fluctuating therapeutic category demand (i.e. CNS)
Takeda/Shire is a ~10% customer
Increased data costs for the Data Solutions group

I do not hold a position with the issuer such as employment, directorship, or consultancy.
I and/or others I advise hold a material investment in the issuer's securities.

Catalyst

Improvements from Strategic Solutions
Eventual recovery of large pharma projects

    show   sort by    
      Back to top